MedPath

evaluation of Niosomal Erythromycin in the Treatment of Acne Vulgaris

Not Applicable
Conditions
acne.
Registration Number
IRCT2017101035524N3
Lead Sponsor
Kerman University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

The inclusion criteria were those with mild to moderate acne vulgaris and 12-35 years old.
The exclusion criteria were as follows: pregnant or lactating women, people with known hypersensitivity to erythromycin and zinc acetate, treatment with oral isotretinoin within last 6 months, oral estrogen compounds within last 3 months, topical retinoid compounds and antibiotics within last 1 month, patients with hirsutism, androgenetic alopecia and polycystic ovary syndrome.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
umber of inflammatory,non-inflammatory acne lesions,quality of life before and after the treatment. Timepoint: 2,4,8,12 weeks. Method of measurement: counting of the inflammatory,noninflammatory and total acne lesions,assessment of quality of life by Cardiff acne disability index ( CADI.
Secondary Outcome Measures
NameTimeMethod
Adverse effects(erythema,burning and itching sensation,peeling). Timepoint: 2,4,8,12 weeks. Method of measurement: by question of patients and physical examination.
© Copyright 2025. All Rights Reserved by MedPath